CLINICAL TRIAL article
Front. Digit. Health
Sec. Health Communications and Behavior Change
Volume 7 - 2025 | doi: 10.3389/fdgth.2025.1502990
Evaluating the effect of mobile applications "My A:Care" and "Smart Coach" on adherence to lipid-lowering treatment in patients with dyslipidemia: A prospective, randomized, open-label clinical study
Provisionally accepted
- Khon Kaen University, Khon Kaen, Thailand
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Dyslipidemia, a key modifiable risk factor for cardiovascular diseases, is managed using lipid-lowering therapies. Medication adherence for dyslipidemia treatment is poor across the globe, impacting treatment effectiveness. This highlights the need for scalable strategies, such as mobile app-based behavioral interventions, to enhance adherence to lipid-lowering therapies. Objective: The study assesses the impact of "My A:Care" and "My A:Care Smart Coach" mobile interventions on adherence to dyslipidemia treatment. Methods: This proof-of-concept, open-label, single-center study randomized 150 patients with suboptimal adherence to dyslipidemia treatment into three groups (1:1:1): My A:Care, My A:Care Smart Coach (intervention), and a no-app control group. Participants were monitored over 12 weeks. The primary objective was to assess changes in medication adherence, with secondary outcomes including changes in lipid parameters and beliefs about lipid-lowering medications. The study also explored the association between adherence and app engagement. Results: At week 12, the Medication Adherence Report with Visual Analog Scale (MARS-5VA) Part 1 scores were modestly, but significantly lower in the control group compared to the intervention groups: Mean (SD); No-App: -0.3 (0.9), Smart Coach: 0.0 (0.7) [p = 0.035], My A:Care-All: 0.0 (0.7) [p = 0.056]. Compared to the control, the intervention groups also showed greater improvements in non-HDL-C levels [% change (SE): My A:Care-All: -5.5% (3.2), Smart Coach: -4.3% (3.7), No-App: -1.8% (3.7)], along with favorable trends in TC, LDL-C, and HDL-C. Conclusion: This proof-of-concept study suggests that the My A:Care and Smart Coach apps may positively impact adherence to lipid-lowering therapy in patients with dyslipidemia. The positive adherence outcomes and potential benefits in lipid control indicate promising early signals that warrant further investigation in larger, confirmatory studies. Clinical Trial registration number: NCT05370703
Keywords: Clinical Trial registration number: NCT05370703 Keywords (6): Dyslipidemia; medication adherence, Medication non-adherence, Mobile Applications, behavioral interventions, Lipid-lowering therapies
Received: 27 Sep 2024; Accepted: 20 Jun 2025.
Copyright: © 2025 Pongchaiyakul. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Chatlert Pongchaiyakul, Khon Kaen University, Khon Kaen, Thailand
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.